{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:53:31Z","timestamp":1785419611024,"version":"3.56.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Autoimmune liver disease (ALD) is a chronic liver disease caused by immune dysfunction in the body. However, no causative or curative medical treatment with proven efficacy exists to cure ALDs, and liver transplantation (LT) remains the only effective treatment available. However, the problem of recurrence of ALDs (rALDs) still remains after LT, which seriously affects the survival rate of the patients. Therefore, clinicians need to be aware of the risk factors affecting rALDs after LT. Therefore, this meta-analysis aims to define the risk factors for rALDs, which include the recurrence of primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic search in Pubmed, Embase, Cochrane library and Web of Science databases was performed from 1980 to 2019. The inclusion criteria were risk factors for developing rALDs after LT. However, case series, case reports, reviews, meta-analysis and studies only including human immunodeficiency virus cases, children, and pregnant patients were excluded.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The electronic database search yielded 1728 results. Sixty-three retrospective cohort studies met the inclusion criteria and 13 were included in the meta-analysis. The final cohort included 5077 patients, and among them, 21.96% developed rALDs. Colectomy before LT, HR 0.59 (95% confidence interval [CI]: 0.37-0.96), cholangiocarcinoma, HR 3.42 (95% CI: 1.88\u20136.21), multiple episodes of acute cellular rejection, HR 2.07 (95% CI: 1.27\u20133.37), model for end-stage liver disease score, HR 1.05 (95% CI: 1.02\u20131.08), use of mycophenolate mofetil, HR 1.46 (95% CI: 1.00\u20132.12) and the use of cyclosporin A, HR 0.69 (95% CI: 0.49\u20130.97) were associated with the risk of rprimary sclerosing cholangitis. In addition, the use of tacrolimus, HR 1.73 (95% CI: 1.00\u20132.99) and cyclosporin A, HR 0.59 (95% CI: 0.39\u20130.88) were associated with the risk of rALD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Multiple risk factors for rALDs were identified, such as colectomy before LT, cholangiocacinoma, multiple episodes of acute cellular rejection, model for end-stage liver disease score, and especially the use of mycophenolate mofetil, cyclosporin A and tacrolimus.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020205","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T15:57:00Z","timestamp":1589903820000},"page":"e20205","source":"Crossref","is-referenced-by-count":20,"title":["Risk factors for recurrent autoimmune liver diseases after liver transplantation"],"prefix":"10.1097","volume":"99","author":[{"given":"Chongfa","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, Dongfang Hospital, Xiamen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruisheng","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xiamen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, 900 Hospital of the Joint Logistics Team, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiucheng","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, 900 Hospital of the Joint Logistics Team, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, 900 Hospital of the Joint Logistics Team, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghua","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, 900 Hospital of the Joint Logistics Team, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, 900 Hospital of the Joint Logistics Team, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengfeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Dongfang Hospital, Xiamen University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Dongfang Hospital, Xiamen University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"R1-20240521","doi-asserted-by":"crossref","first-page":"b3305","DOI":"10.1136\/bmj.b3305","article-title":"Autoimmune liver disease for the non-specialist","volume":"339","author":"Decock","year":"2009","journal-title":"BMJ"},{"key":"R2-20240521","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.4254\/wjh.v8.i28.1157","article-title":"Cirrhosis and autoimmune liver disease: current understanding","volume":"8","author":"Liberal","year":"2016","journal-title":"World J Hepatol"},{"key":"R3-20240521","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1432-2277.2008.00729.x","article-title":"Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far?","volume":"22","author":"Schreuder","year":"2009","journal-title":"Transplant Int"},{"key":"R4-20240521","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jhep.2009.11.027","article-title":"Primary biliary cirrhosis: a 2010 update","volume":"52","author":"Poupon","year":"2010","journal-title":"J Hepatol"},{"issue":"(5)","key":"R5-20240521","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1432-2277.2007.00628.x","article-title":"The impact of disease recurrence on graft survival following liver transplantation: a single centre experience","volume":"21","author":"Rowe","year":"2008","journal-title":"Transplant Int"},{"key":"R6-20240521","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000007776","article-title":"Liver transplantation in primary biliary cirrhosis: risk assessment and 11-year follow-up","volume":"62","author":"Rust","year":"2000","journal-title":"Digestion"},{"key":"R7-20240521","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1600-6143.2009.03006.x","article-title":"Cyclosporine a protects against primary biliary cirrhosis recurrence after liver transplantation","volume":"10","author":"Montano-Loza","year":"2010","journal-title":"Am J Transplantation"},{"key":"R8-20240521","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0029-1192052","article-title":"Liver transplantation: the current situation","volume":"29","author":"Adam","year":"2009","journal-title":"Semin Liver Dis"},{"key":"R9-20240521","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.lts.2003.09.018","article-title":"Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry","volume":"9","author":"Adam","year":"2003","journal-title":"Liver Transpl"},{"key":"R10-20240521","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hep.510300501","article-title":"Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis","volume":"30","author":"Graziadei","year":"1999","journal-title":"Hepatology"},{"key":"R11-20240521","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2012.04.015","article-title":"Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)","volume":"57","author":"Adam","year":"2012","journal-title":"J Hepatol"},{"key":"R12-20240521","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMra050408","article-title":"Autoimmune hepatitis","volume":"354","author":"Krawitt","year":"2006","journal-title":"New Engl J Med"},{"key":"R13-20240521","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.3748\/wjg.14.3388","article-title":"Transplantation in autoimmune liver diseases","volume":"14","author":"Mottershead","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R14-20240521","first-page":"315","article-title":"An analysis of the OPTN\/UNOS Liver Transplant Registry","author":"Futagawa","year":"2004","journal-title":"Clin Transpl"},{"key":"R15-20240521","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/jlts.2002.32981","article-title":"Incidence and recurrence of autoimmune\/alloimmune hepatitis in liver transplant recipients","volume":"8","author":"Molmenti","year":"2002","journal-title":"Liver Transpl"},{"key":"R16-20240521","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/lt.20910","article-title":"Recurrence of autoimmune liver disease after liver transplantation: a systematic review","volume":"12","author":"Gautam","year":"2006","journal-title":"Liver Transpl"},{"key":"R17-20240521","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00423-017-1646-x","article-title":"Optimal literature search for systematic reviews in surgery","volume":"403","author":"Goossen","year":"2018","journal-title":"Langenbecks Arch Surg"},{"key":"R18-20240521","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/00365521.2017.1421705","article-title":"Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study","volume":"53","author":"Lindstr\u00f6m","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"R19-20240521","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1155\/2010\/830291","article-title":"The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation--a single-centre experience","volume":"24","author":"Moncrief","year":"2010","journal-title":"Can J Gastroenterol"},{"key":"R20-20240521","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jhep.2015.07.005","article-title":"Risk factors for recurrent primary sclerosing cholangitis after liver transplantation","volume":"63","author":"Ravikumar","year":"2015","journal-title":"J Hepatol"},{"key":"R21-20240521","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/lt.24496","article-title":"Recurrent primary sclerosing cholangitis in the adult-to-adult living donor liver transplantation Cohort study: comparison of risk factors between living and deceased donor recipients","volume":"22","author":"Gordon","year":"2016","journal-title":"Liver Transpl"},{"key":"R22-20240521","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/lt.24350","article-title":"Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis","volume":"22","author":"Hildebrand","year":"2016","journal-title":"Liver Transpl"},{"key":"R23-20240521","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/lt.21313","article-title":"Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course","volume":"14","author":"Campsen","year":"2008","journal-title":"Liver Transpl"},{"key":"R24-20240521","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jhep.2015.07.038","article-title":"Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence","volume":"63","author":"Bosch","year":"2015","journal-title":"J Hepatol"},{"key":"R25-20240521","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/lt.20123","article-title":"Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation","volume":"10","author":"Neuberger","year":"2004","journal-title":"Liver Transpl"},{"key":"R26-20240521","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2018.10.001","article-title":"Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival","volume":"156","author":"Montano-Loza","year":"2019","journal-title":"Gastroenterology"},{"key":"R27-20240521","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep4.1037","article-title":"Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: a Japanese multicenter retrospective study","volume":"1","author":"Kogiso","year":"2017","journal-title":"Hepatology Communications"},{"key":"R28-20240521","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/ajt.13583","article-title":"Long-Term Outcomes of Living-Donor Liver Transplantation for Primary Biliary Cirrhosis: a Japanese Multicenter Study","volume":"16","author":"Egawa","year":"2016","journal-title":"Am J Transplantation"},{"key":"R29-20240521","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/S0618-8278(19)30146-X","article-title":"Preventive administration of ursodeoxycholic acid after liver transplantation for primary biliary cholangitis prevents disease recurrence and prolongs graft survival","volume":"70","author":"Corpechot","year":"2019","journal-title":"J Hepatol"},{"key":"R30-20240521","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1440-1746.2004.03490.x","article-title":"Biliary disease after liver transplantation: the experience of the King Faisal Specialist Hospital and Research Center, Riyadh","volume":"20","author":"Khuroo","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"R31-20240521","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/lt.21960","article-title":"Primary biliary cirrhosis after liver transplantation: Influence of immunosuppression and human leukocyte antigen locus disparity","volume":"16","author":"Manousou","year":"2010","journal-title":"Liver Transpl"},{"key":"R32-20240521","first-page":"636","article-title":"Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation","volume":"49","author":"Steenstraten","year":"2019","journal-title":"#N\/A"},{"key":"R33-20240521","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/lt.21107","article-title":"Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma","volume":"13","author":"Mantel","year":"2007","journal-title":"Liver Transpl"},{"key":"R34-20240521","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1097\/00007890-199811270-00006","article-title":"Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process?","volume":"66","author":"Jeyarajah","year":"1998","journal-title":"Transplantation"},{"key":"R35-20240521","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"key":"R36-20240521","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1097\/TXD.0000000000000693","article-title":"Outcomes of liver transplant recipients with autoimmune liver disease using long-term dual immunosuppression regimen without corticosteroid","volume":"3","author":"Satapathy","year":"2017","journal-title":"Transplant Direct"},{"key":"R37-20240521","first-page":"485","article-title":"Systematic review: recurrent autoimmune liver diseases after liver transplantation","volume":"45","author":"Montano-Loza","year":"2017","journal-title":"#N\/A"},{"key":"R38-20240521","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cgh.2012.12.027","article-title":"Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease","volume":"11","author":"J\u00f8rgensen","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R39-20240521","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/ibd\/izx096","article-title":"Natural history of established and de novo inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis","volume":"24","author":"Mouchli","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"R40-20240521","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/01.mcg.0000177230.13770.4e","article-title":"Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid","volume":"39","author":"Talwalkar","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"R41-20240521","first-page":"1426","article-title":"Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation","volume":"32","author":"Montano-Loza","year":"2012","journal-title":"#N\/A"},{"key":"R42-20240521","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the study of liver diseases","author":"Mack","year":"2019","journal-title":"Hepatology"},{"key":"R43-20240521","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG clinical guideline: primary sclerosing cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R44-20240521","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1053\/j.gastro.2019.02.047","article-title":"Recurrence of primary biliary cholangitis after liver transplantation: is tacrolimus really worse than other drugs?","volume":"156","author":"Rayar","year":"2019","journal-title":"Gastroenterology"},{"key":"R47-20240521","doi-asserted-by":"crossref","first-page":"6925","DOI":"10.3748\/wjg.v22.i30.6925","article-title":"Risk factor for ischemic-type biliary lesion after ABO-incompatible living donor liver transplantation","volume":"22","author":"Bang","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R48-20240521","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/hep.510290427","article-title":"Recurrence of primary sclerosing cholangitis following liver transplantation","volume":"29","author":"Graziadei","year":"1999","journal-title":"Hepatology"},{"key":"R49-20240521","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1097\/TXD.0000000000000751","article-title":"Long-term prognosis and recurrence of primary sclerosing cholangitis after liver transplantation: a single-center experience","volume":"3","author":"Ueda","year":"2017","journal-title":"Transplant Direct"},{"key":"R50-20240521","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S0168-8278(13)60102-6","article-title":"Combination of calcineurin inhibitors and genotypes at the IL12A locus influences risk of recurrent primary biliary cirrhosis after liver transplantation","volume":"5","author":"Carbone","year":"2013","journal-title":"J Hepatol"},{"key":"R51-20240521","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.3748\/wjg.v24.i43.4939","article-title":"Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease","volume":"24","author":"Bajer","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R52-20240521","first-page":"S108","article-title":"Positive cross match and older liver grafts are associated with recurrence of primary sclerosing cholangitis after liver transplantation","volume":"9","author":"El Moghazy","year":"2015","journal-title":"Hepatol Int"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T20:05:35Z","timestamp":1716321935000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020205"}},"subtitle":["A meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":50,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020205","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,15]]}}}